 | « Back to article | Print this article |
Pharma-major Wockhardt Ltd has set up a sales and marketing subsidiary in the United States to drive its business in the world's largest pharmaceutical market.
"We are seeking an exponential growth in our US business over the next few years," Wockhardt chairman Habil Khorakiwala said in a release on Tuesday.
"Towards this end, we are beefing up the research and development, manufacturing, regulatory and legal infrastructure in India, and establishing sales and marketing subsidiary in the US," he said.
More than 150 professionals at various levels at Wockhardt in India are supporting the company's US generics business by working on non-infringing technologies, filing abbreviated new drug applications and liaising with US regulatory bodies, he added.
Arthur Maher, a marketing professional with over 20 years of experience in the generic pharmaceutical industry, has been appointed as president - sales and marketing for Wockhardt USA Inc.
The company has also relocated Sanjay Patel, president - corporate scientific affairs, from India to US. He would guide Wockhardt's scientific and technical affairs in India, Europe and the US.
Ramesh Sesha, senior vice president, intellectual property, would also move to the US office.
Wockhardt currently sells four products in the US -- Ranitidine, Enalapril, Bethanecol chloride and Captopril. It filed six new ANDAs with USFDA last year and plans to file 15 ANDAs this year.